fibroblast growth factor 21 in migraine headache

Serum level of fibroblast growth factor 21 evaluation in patients with migraine headache treated by sodium valproate

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190804044429N3

Enrollment

Registered

2020-10-07

Start date

2020-04-04

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migrain. Migraine

Interventions

Intervention group: Sodium valproate 500 mg every 12 hours (1000 mg daily) for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with recently migraine headache (with or without aura) candidate receiving prophylaxis regimen with sodium valproate

Exclusion criteria

Exclusion criteria: Headache sub-types other than migraine Pregnancy Breast feeding Renal and Liver dysfunction

Design outcomes

Primary

Measure	Time frame
FGF-21 serum levels. Timepoint: on 0 and 48 days of the study. Method of measurement: Elisa kite.;Headache severity. Timepoint: On 0 and 48 days of the study. Method of measurement: VAS scale.	—

Secondary

Measure	Time frame
Clinical response evaluation. Timepoint: On 0 and 48 days of the study. Method of measurement: MIDAS questionnaire.;Side effects profile. Timepoint: weekly. Method of measurement: history taking.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Ghazaeian

Mazandaran University of Medical Sciences

ghazaeianm@gmail.com+98 11 3334 3011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026